Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, alone or with irinotecan, temozolomide/irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Bradley DeNardo, Jennie Foster, Navin R. Pinto, Giselle Linda Saulnier Sholler, Kieuhoa Tran Vo, Ami Vijay Desai, Jessica Sun, Lars M. Wagner, Margaret E Macy, Rajen Mody, Javier E. Oesterheld, Thomas Cash, Roma Bhuta, Eveline Barbieri, Andrew DJ Pearson, Ludimila Cavalcante, Francis J. Giles, Rishi Ramesh Lulla
Institutions: Brown University, Hasbro Children's Hospital, Baylor College of Medicine, Seattle Children's Hospital, Carolinas Medical Center, Levine Children's Hospital, University of California, San Francisco, University of Chicago Medical Center, Duke Medical Center, Children's Hospital Colorado, University of Michigan, Emory University, Children's Healthcare of Atlanta, Texas Children's Hospital, Institute of Cancer Research, Royal Marsden Hospital, Actuate Therapeutics, Inc. (United States)
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Actuate Therapeutics
OpenAlex ID: W4281705020